Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TPST Tempest Therapeutics Inc.

Market Closed 10-16 16:00:00 EDT

0.6242

-0.0108

-1.70%

盘后0.6299

+0.0057+0.91%

19:30 EDT

High0.6688	Low0.6201	Vol67.43K
Open0.6680	D1 Closing0.6350	Amplitude7.67%
Mkt Cap10.54M	Tradable Cap5.99M	Total Shares16.89M
T/O42.75K	T/O Rate0.70%	Tradable Shares9.60M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TPST","market":"US","secType":"STK","nameCN":"Tempest Therapeutics Inc.","latestPrice":0.6242,"timestamp":1792180800000,"preClose":0.635,"halted":0,"volume":67432,"hourTrading":{"tag":"盘后","latestPrice":0.6299,"preClose":0.6242,"latestTime":"19:30 EDT","volume":1647,"amount":1037.2,"timestamp":1792193404171,"change":0.0057,"changeRate":0.009132,"amplitude":0.009292},"delay":0,"changeRate":-0.017007874015748083,"floatShares":9598409,"shares":16889800,"eps":-4.561698,"marketStatus":"Market Closed","change":-0.0108,"latestTime":"10-16 16:00:00 EDT","open":0.668,"high":0.6688,"low":0.6201,"amount":42753.8232984,"amplitude":0.076693,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.561698,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792396800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.635,"preHourTrading":{"tag":"盘前","latestPrice":0.665,"preClose":0.635,"latestTime":"09:18 EDT","volume":1245,"amount":831.900036,"timestamp":1792156710822,"change":0.03,"changeRate":0.047244,"amplitude":0.03937},"postHourTrading":{"tag":"盘后","latestPrice":0.6299,"preClose":0.6242,"latestTime":"19:30 EDT","volume":1647,"amount":1037.2,"timestamp":1792193404171,"change":0.0057,"changeRate":0.009132,"amplitude":0.009292},"volumeRatio":0.383347,"impliedVol":1.4125,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TPST/wiki","defaultTab":"wiki","newsList":[{"id":"2675388341","title":"Tempest Therapeutics Appoints John W. Frederick to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2675388341","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675388341?lang=en_us&edition=fundamental","pubTime":"2026-10-14 20:02","pubTimestamp":1791979373,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics appoints John W. Frederick to board of directorsTempest Therapeutics named John W. Frederick to its board of directors.Frederick most recently served as CFO of Skillsoft, overseei","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nNDL4MZH0W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","BCDF","LU2210150020.SGD","BK4112","LU0314104364.USD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","BK4139","IE00BKPKM429.USD","BK4130","SKIL","SG9999014013.SGD","LU2095319765.USD","SG9999014021.USD","IE00BQXX3C00.GBP","SG9999014039.USD","SG9999014005.SGD","BK4585","IE00BN0W2T93.GBP","NDAQ","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","BK4588","TPST","IE00BN0W2V16.EUR","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675349099","title":"Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise","url":"https://stock-news.laohu8.com/highlight/detail?id=2675349099","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675349099?lang=en_us&edition=fundamental","pubTime":"2026-10-14 20:00","pubTimestamp":1791979204,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261014:nTUA2SJJK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673060218","title":"Sensorion Names Louis J. Arcudi III CFO, Replacing Laurene Danon","url":"https://stock-news.laohu8.com/highlight/detail?id=2673060218","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673060218?lang=en_us&edition=fundamental","pubTime":"2026-10-07 13:30","pubTimestamp":1791351021,"startTime":"0","endTime":"0","summary":"Sensorion names Louis J. Arcudi III CFO, replacing Laurene DanonSensorion named Louis J. Arcudi III chief financial officer effective Oct. 7, 2026, based in the Boston area.Arcudi was CFO of Amolyt Ph","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL6yGKDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0963555726.SGD","LU1003076772.USD","LU0047473722.EUR","LU0526926950.USD","IE00BFTCPJ56.SGD","LU0976567544.SGD","LU1267930227.SGD","LU1481600234.SGD","IE00BJT1NW94.SGD","LU1496350171.SGD","LU0496365809.HKD","LU0158827948.USD","LU0171276677.USD","LU0128525689.USD","IE00B3T34201.USD","AZN.UK","LU0128525929.USD","LU0266013472.USD","LU1046234339.USD","LU0889565080.SGD","LU0920783379.SGD","LU1051770623.HKD","LU0310799852.SGD","LU2355687059.USD","LU1267930813.SGD","TPST","LU1301847155.USD","LU0882574055.USD","LU0171293334.USD","LU0823399737.USD","LU1355424745.HKD","LU2279689827.SGD","LU1019632923.USD","LU1481599808.USD","LU2112291526.USD","LU0345777147.USD","LU0553294199.USD","LU1487256676.USD","LU2125909593.SGD","LU0211326755.USD","LU0661504455.SGD","LU0949170426.SGD","LU0957799991.USD","LU0857590862.USD","LU0792757196.USD","SG9999001176.USD","IE00BKPKM643.USD","LU1880407215.USD","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672493557","title":"Tempest Therapeutics Names Nancy Freda-Smith to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2672493557","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672493557?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:18","pubTimestamp":1790972325,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics names Nancy Freda-Smith to boardTempest Therapeutics named Nancy Freda Smith as a director, effective Sept. 22, 2026.Disclaimer:This news brief was created by Public Technologies ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6DHMf1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671572812","title":"Tempest Therapeutics Appoints Nancy Freda-Smith to Board, Names Her Audit Committee Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2671572812","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671572812?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:06","pubTimestamp":1790625993,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics appoints Nancy Freda-Smith to board, names her audit committee chairTempest Therapeutics appointed Nancy Freda-Smith to its board of directors.Freda-Smith will serve as chair of t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL6PWxvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670424113","title":"Tempest Therapeutics - Prospectus Filed for Offer and Resale of up to 9,534,164 Shares of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424113?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:31","pubTimestamp":1790368270,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H0LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669914614","title":"Tempest Therapeutics Inc : H.c. Wainwright Cuts Target Price to $7 from $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2669914614","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669914614?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:18","pubTimestamp":1790263113,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nFWN45G12Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483478","title":"Tempest Therapeutics Appoints Nancy Freda-Smith to Board, Names Her Audit Committee Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483478","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483478?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165045,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics appoints Nancy Freda-Smith to board, names her audit committee chairTempest Therapeutics appointed Nancy Freda-Smith to its board of directors.Freda-Smith will serve as chair of t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL7YSwK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","STYL","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","BK4202","BK4112","SG9999014005.SGD","LU2095319765.USD","RL","BCDF","TPST","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","SG9999014021.USD","LU2210150020.SGD","IE00BQXX3F31.USD","LU0054578231.USD","BK4585","IE00B3QW5Z07.USD","LU0963586101.USD","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0006061336.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669978483","title":"Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669978483","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669978483?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:00","pubTimestamp":1790164801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA9NVFL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668299752","title":"Tempest Therapeutics Signs Exclusive Option Deal with Senlang for CD7-Targeted in Vivo CAR-T Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2668299752","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668299752?lang=en_us&edition=fundamental","pubTime":"2026-09-18 05:06","pubTimestamp":1789679175,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics signs exclusive option deal with Senlang for CD7-targeted in vivo CAR-T platformTempest Therapeutics entered an exclusive option agreement with Hebei Senlang Biotechnology to lice","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDLmQCqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668686935","title":"Tempest Therapeutics Special Meeting Adjourned After Proposal Fell Short of 75% Vote Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2668686935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668686935?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:38","pubTimestamp":1789591092,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics special meeting adjourned after proposal fell short of 75% vote thresholdTempest Therapeutics held a reconvened special shareholder meeting on Sept. 15, 2026 to vote on a charter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL8Cnm5F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667335600","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2667335600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667335600?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:12","pubTimestamp":1789557137,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  stock was 45% higher in Wednesday's premarket activity, a day after the company said it signed an exclusive option agreement with China's Hebei Senlang Biotechnology.ReTo Eco-Solutions  shares were up over 41% following a more than 676% rise in the prior session.YYForce  stock was 23% higher after the company reported its estimated total and net assets.Future FinTech Group  shares were up 12%, swinging from a 29% fall at Tuesday's close.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FTFT","YFOR","BK4139","BK4122","RETO","BK4164","TPST","BK4120","BK4011"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667627808","title":"Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang","url":"https://stock-news.laohu8.com/highlight/detail?id=2667627808","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667627808?lang=en_us&edition=fundamental","pubTime":"2026-09-16 05:45","pubTimestamp":1789508730,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics  signed an exclusive option agreement with China's Hebei Senlang Biotechnology to license a clinical-stage technology that delivers CAR-T cancer treatments directly inside the body, along with a portfolio of related drug candidates.The portfolio includes an early-stage treatment that targets two proteins linked to multiple myeloma and is now being tested in a phase 1 study, Tempest said Tuesday in a statement. Other candidates in the group are aimed at blood cancers and autoimmune diseases, the company said.Tempest said it will continue to evaluate phase 1 results with Senlang during the option period.The company also disclosed in a regulatory filing that it raised about $2.5 million last week through a private placement of prefunded and common stock warrants.Tempest shares rose 35% in after-hours trading.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","TPST","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667862498","title":"Tempest Secures Exclusive Option to License Clinical-Stage Cd7-Targeted Lentiviral in Vivo CAR-T Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2667862498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667862498?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:05","pubTimestamp":1789502700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1GSKBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667624994","title":"Tempest Therapeutics Inc: Entered into an Exclusive Option Agreement with Hebei Senlang Biotechnology Co., Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2667624994","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667624994?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:05","pubTimestamp":1789502700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1GSKBQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667462498","title":"Tempest Therapeutics - no Grade 3 or Higher Cytokine Release Syndrome or Neurotoxicity as of Aug 25, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667462498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667462498?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:05","pubTimestamp":1789502700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nTUA1GSKBQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TPST","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666228095","title":"Tempest Therapeutics announces $7.5M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666228095","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666228095?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:30","pubTimestamp":1789129829,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics (TPST) announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,105,591 shares ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-announces-7-5m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-announces-7-5m-private-placement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","TPST","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666737521","title":"Tempest Therapeutics Prices $2.5 Million Private Placement at $0.81 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2666737521","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666737521?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:01","pubTimestamp":1789128119,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics prices $2.5 million private placement at $0.81 per shareTempest Therapeutics priced a private placement of 3,105,591 common shares or pre-funded warrants at USD 0.81 with Series C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL69YqFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","BK4112","SG9999014005.SGD","LU2095319765.USD","BCDF","TPST","IE00BN0W2T93.GBP","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","SG9999014021.USD","IE00BQXX3F31.USD","BK4585","BK4139","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666521252","title":"Tempest Therapeutics Announces up to $7.5 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2666521252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666521252?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA3KQ0DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TPST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378956","title":"Tempest Therapeutics CEO to Present at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378956","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665378956?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:34","pubTimestamp":1788870887,"startTime":"0","endTime":"0","summary":"Tempest Therapeutics CEO to present at H.C. Wainwright Global Investment ConferenceTempest Therapeutics’ CEO Matt Angel will present at the H.C. Wainwright 28th Annual Global Investment Conference on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL8gk7Fj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","NDAQ","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","TPST","LU2095319765.USD","LU2210149790.SGD","IE00BQXX3F31.USD","BK4139","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","BCDF","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014013.SGD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tempesttx.com","stockEarnings":[{"period":"1week","weight":-0.1788},{"period":"1month","weight":-0.4841},{"period":"3month","weight":-0.3538},{"period":"6month","weight":-0.6815},{"period":"1year","weight":-0.9437},{"period":"ytd","weight":-0.7825}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.012727},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.032927},{"month":3,"riseRate":0.461538,"avgChangeRate":0.000618},{"month":4,"riseRate":0.307692,"avgChangeRate":-0.113004},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.011916},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.124765},{"month":7,"riseRate":0.214286,"avgChangeRate":-0.03977},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.030843},{"month":9,"riseRate":0.5,"avgChangeRate":-0.071754},{"month":10,"riseRate":0.428571,"avgChangeRate":0.860413},{"month":11,"riseRate":0.384615,"avgChangeRate":-0.081423},{"month":12,"riseRate":0.307692,"avgChangeRate":-0.062561}],"exchange":"NASDAQ","name":"Tempest Therapeutics Inc.","nameEN":"Tempest Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tempest Therapeutics Inc.,TPST,Tempest Therapeutics Inc.股票,Tempest Therapeutics Inc.股票老虎,Tempest Therapeutics Inc.股票老虎国际,Tempest Therapeutics Inc.行情,Tempest Therapeutics Inc.股票行情,Tempest Therapeutics Inc.股价,Tempest Therapeutics Inc.股市,Tempest Therapeutics Inc.股票价格,Tempest Therapeutics Inc.股票交易,Tempest Therapeutics Inc.股票购买,Tempest Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tempest Therapeutics Inc.(TPST),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tempest Therapeutics Inc.(TPST) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}